Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS NASDAQ:ADAG NASDAQ:STRO NASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$5.09+4.3%$3.98$1.16▼$5.12$681.56M0.761.35 million shs2.24 million shsADAGAdagene$3.70+1.1%$3.73$1.30▼$4.75$173.43M0.57180,542 shs29,317 shsSTROSutro Biopharma$39.60-3.2%$28.46$6.74▼$41.88$677.79M1.63245,179 shs219,661 shsTLRYTilray Brands$5.46+0.9%$6.61$3.51▼$23.20$630.53M1.947.95 million shs3.25 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+4.30%+6.49%+30.51%+51.49%+317.21%ADAGAdagene+1.09%+2.49%-3.65%+29.82%+115.12%STROSutro Biopharma-3.20%+5.07%+51.20%+153.52%+385.83%TLRYTilray Brands+0.92%-5.21%-18.75%-27.10%+21.23%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$5.09+4.3%$3.98$1.16▼$5.12$681.56M0.761.35 million shs2.24 million shsADAGAdagene$3.70+1.1%$3.73$1.30▼$4.75$173.43M0.57180,542 shs29,317 shsSTROSutro Biopharma$39.60-3.2%$28.46$6.74▼$41.88$677.79M1.63245,179 shs219,661 shsTLRYTilray Brands$5.46+0.9%$6.61$3.51▼$23.20$630.53M1.947.95 million shs3.25 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+4.30%+6.49%+30.51%+51.49%+317.21%ADAGAdagene+1.09%+2.49%-3.65%+29.82%+115.12%STROSutro Biopharma-3.20%+5.07%+51.20%+153.52%+385.83%TLRYTilray Brands+0.92%-5.21%-18.75%-27.10%+21.23%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.00Buy$11.29121.72% UpsideADAGAdagene 3.00Buy$8.00116.22% UpsideSTROSutro Biopharma 2.85Moderate Buy$40.782.97% UpsideTLRYTilray Brands 2.25Hold$11.50110.62% UpsideCurrent Analyst Ratings BreakdownLatest ADAG, TLRY, STRO, and ACRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026STROSutro Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/5/2026ACRSAclaris Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$7.00 ➝ $11.005/5/2026ACRSAclaris Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.005/4/2026ACRSAclaris Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/4/2026STROSutro Biopharma Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/1/2026STROSutro Biopharma Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/30/2026STROSutro Biopharma MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$50.004/30/2026STROSutro Biopharma MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$50.004/29/2026TLRYTilray Brands Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/29/2026ACRSAclaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$8.00 ➝ $10.004/23/2026STROSutro Biopharma Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$35.00 ➝ $41.00(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$7.83M90.79N/AN/A$1.03 per share4.94ADAGAdagene$7.67M22.86N/AN/A$0.75 per share4.93STROSutro Biopharma$102.48M6.40N/AN/A($15.43) per share-2.57TLRYTilray Brands$821.31M0.77$1.46 per share3.74$14.04 per share0.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$64.92M-$0.56N/AN/AN/A-832.58%-55.89%-38.49%N/AADAGAdagene-$17.61MN/AN/AN/AN/AN/AN/AN/AN/ASTROSutro Biopharma-$191.09M-$26.10N/AN/AN/A-186.45%N/A-79.02%5/14/2026 (Estimated)TLRYTilray Brands-$2.19B-$13.65N/AN/AN/A-156.51%-3.31%-2.42%7/27/2026 (Estimated)Latest ADAG, TLRY, STRO, and ACRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026STROSutro Biopharma-$2.7363N/AN/AN/A$8.89 millionN/A5/7/2026Q1 2026ACRSAclaris Therapeutics-$0.16-$0.15+$0.01-$0.15$1.32 million$2.00 million4/1/2026Q4 2025ADAGAdagene-$0.28-$0.0440+$0.2360-$0.0440$17.50 million$3.84 million4/1/2026Q3 2026TLRYTilray Brands-$0.14-$0.24-$0.10-$0.24$201.35 million$206.73 million2/26/2026Q4 2025ACRSAclaris Therapeutics-$0.15-$0.1614-$0.0114-$0.16$2.07 million$1.30 million2/14/2026Q4 2025ADAGAdageneN/A-$0.0440N/A-$0.0440N/A$3.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/AADAGAdageneN/AN/AN/AN/AN/ASTROSutro BiopharmaN/AN/AN/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A4.034.03ADAGAdagene0.033.073.07STROSutro BiopharmaN/A2.012.01TLRYTilray Brands0.192.791.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%ADAGAdagene9.51%STROSutro Biopharma96.99%TLRYTilray Brands9.35%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics5.60%ADAGAdagene21.20%STROSutro Biopharma3.60%TLRYTilray Brands0.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100139.66 million131.84 millionOptionableADAGAdagene26047.39 million37.34 millionNot OptionableSTROSutro Biopharma24016.57 million15.97 millionOptionableTLRYTilray Brands2,842116.55 million115.57 millionOptionableADAG, TLRY, STRO, and ACRS HeadlinesRecent News About These CompaniesBest Cannabis Stocks To Follow Now - May 12th20 minutes ago | americanbankingnews.comTilray Brands stock is in a freefall: key reasons and what nextMay 13 at 9:04 AM | invezz.comITilray Brands stock is in a freefall: key reasons and what nextMay 13 at 8:57 AM | invezz.comIBlue Point Brewing Launches Magic Hour IPA—A Bright, Tropical 6% ABV Sipper for Golden HourMay 12 at 7:48 AM | finance.yahoo.comBlue Point Brewing Launches Magic Hour IPA—A Bright, Tropical 6% ABV Sipper for Golden HourMay 12 at 7:00 AM | globenewswire.comIt's been 5 years since Tilray merged with Aphria to create a global cannabis leader. Here's how it's done since thenMay 11 at 4:45 PM | msn.comPromising Cannabis Stocks To Follow Today - May 11thMay 11 at 1:08 PM | marketbeat.comIt's Been 5 Years Since Tilray Merged With Aphria to Create a "Global Cannabis Leader." Here's How It's Done Since ThenMay 11 at 11:45 AM | fool.comBest Cannabis Stocks To Follow Today - May 10thMay 10, 2026 | marketbeat.comSBI Securities Co. Ltd. Has $255,000 Stock Holdings in Tilray Brands, Inc. $TLRYMay 10, 2026 | marketbeat.comArizona State Retirement System Sells 276,014 Shares of Tilray Brands, Inc. $TLRYMay 10, 2026 | marketbeat.comCannabis Stocks To Research - May 9thMay 9, 2026 | marketbeat.comTilray Brands (NASDAQ:TLRY) Trading Down 1.8% - Here's WhyMay 8, 2026 | marketbeat.comTop Cannabis Stocks To Watch Today - May 8thMay 8, 2026 | marketbeat.comTilray Brands (NASDAQ:TLRY) Trading Down 1.7% - Here's WhyMay 7, 2026 | marketbeat.com1 Wall Street Analyst Thinks Tilray Will Soar Nearly 75%. Is It a Buy Now?May 7, 2026 | fool.comWidmer Brothers Launches “Stay Sunny” Campaign, a Full Brand Refresh Across Its PortfolioMay 7, 2026 | finance.yahoo.comTilray Brands, Inc. (TLRY) Is a Trending Stock: Facts to Know Before Betting on ItMay 7, 2026 | finance.yahoo.comTilray Brands, Inc. (TLRY) Is a Trending Stock: Facts to Know Before Betting on ItMay 7, 2026 | zacks.comWidmer Brothers Launches “Stay Sunny” Campaign, a Full Brand Refresh Across Its PortfolioMay 7, 2026 | financialpost.comFWidmer Brothers Launches “Stay Sunny” Campaign, a Full Brand Refresh Across Its PortfolioMay 7, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesA Quiet Outperformer With a Catastrophe CaveatBy Peter Frank | April 14, 2026The Cannabis Sector's Billion-Dollar Tax CutBy Jeffrey Neal Johnson | April 23, 2026Palantir Is Down 30%: Noise? Or a Signal to Accumulate?By Chris Markoch | April 28, 2026Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong MomentumBy Chris Markoch | May 10, 2026Credo Stock Flashes Strong Bullish Signal—Upswing Just StartingBy Thomas Hughes | April 21, 2026ADAG, TLRY, STRO, and ACRS Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$5.09 +0.21 (+4.30%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$5.36 +0.27 (+5.28%) As of 04:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Adagene NASDAQ:ADAG$3.70 +0.04 (+1.09%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$3.70 0.00 (0.00%) As of 05/13/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.Sutro Biopharma NASDAQ:STRO$39.60 -1.31 (-3.20%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$39.78 +0.18 (+0.47%) As of 05/13/2026 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.Tilray Brands NASDAQ:TLRY$5.46 +0.05 (+0.92%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$5.45 -0.01 (-0.18%) As of 04:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Upside Expands as AI Feedback Loop Intensifies Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? D-Wave Earnings Looked Weak, But Investors May Be Missing This A Quantum Shift: Why Speculative Money Is Ditching AI Plug Power Flips The Switch On Profitability Reading the Stripes: Is The Industrial Recession Over? How Bad Could Tesla’s Cybertruck Recall Be for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
